The Sheltzer Lab at Stanford University is seeking a postdoctoral researcher to study cancer vulnerabilities and small-molecule therapeutics. Multiple projects are available, broadly focused on understanding how genetic alterations create selective dependencies and how drugs can be used to target them.
Cryo‑EM and Protein Biochemistry (Rogala Lab, Stanford) — https://rogala.stanford.edu.
Utkan Demirci is a professor at Stanford University School of Medicine and serves as the interim division chief and co-director of the Canary Center for Cancer Early Detection in the Department of Radiology. His group focuses on developing innovative microfluidic biomedical technology platforms with broad applications to multiple diseases. Some of his inventions have already been translated into Food and Drug Administration-approved products serving patients. He has mentored and trained many successful scientists, entrepreneurs, and academicians.
The research interests of the molecular imaging instrumentation lab are to create novel instrumentation and software algorithms for in vivo imaging of molecular signatures of disease in humans and small laboratory animals. These new cameras efficiently image radiation emissions in the form of positrons, annihilation photons, gamma rays, and/or light emitted from molecular contrast agents that were introduced into the body and distributed in the subject tissues.
Our research focus is in computational systems biology, primarily in cancer and more recently in neurodegenerative diseases. We develop and apply methods to understand biological processes underlying disease, using high-throughput genomic and proteomic datasets and integrating them with phenotypes and clinical outcomes. A key interest is dissecting how the cellular composition and organization of tissues affects their behaviour in disease; and how these things might be targeted for therapy or diagnostic purposes.
The overarching research goal of the Diehn lab is to develop and translate novel diagnostic assays and therapies to improve personalized treatment of cancer patients. We have a major focus on the development and application of liquid biopsy technologies for human cancers, with a particular emphasis on lung cancers and circulating tumor DNA (ctDNA). We also investigate mechanisms of treatment resistance to radiotherapy, immunotherapy, and targeted agents.
The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). In parallel, the lab also investigates normal human hematopoiesis and hematopoietic stem cells. Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior.
